From Alphastreet - Earnings Decoded. Market Intelligence Delivered · AlphaStreet Newsdesk · · 40s
Milestone Pharmaceuticals Reports Narrower Q3 Loss
Milestone Pharmaceuticals Inc. reported a narrower-than-expected Q3 2026 loss of $0.18 per share, beating analyst estimates by 18.2%.
In brief
Milestone Pharmaceuticals Inc. reported a narrower-than-expected Q3 2026 loss of $0.18 per share, beating analyst estimates by 18.2%. Milestone Pharmaceuticals Inc. reported a narrower-than-expected Q3 2026 loss of $0.18 per share, beating analyst estimates by 18.2%. Originally reported by Alphastreet - Earnings…
Q3 2026 Financial Results
Milestone Pharmaceuticals Inc. reported a Q3 2026 loss of $0.18 per share, beating analyst expectations by 18.2%.
Revenue and Net Loss Figures
The company generated $3.0M in revenue and a net loss of $25.8M for the quarter.
Stock Performance
Shares declined 1.1% to $0.66 following the results.
Year-Over-Year Loss Increase
The per-share loss widened to $0.18 from $0.12 in Q3 2025, a 50.0% year-over-year increase.
The short version
Milestone Pharmaceuticals Inc. reported a narrower-than-expected Q3 2026 loss of $0.18 per share, beating analyst estimates by 18.2%.
